Pune: Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, has signed a Memorandum of Understanding (MoU) with medical device innovation studio Embryyo Technologies, to jointly pursue opportunities in the multi-billion-dollar AI-enabled medical devices market.
Vyome-Embryyo Partnership to Advance AI-Enabled Medical Devices
The collaboration will integrate Vyome’s healthcare expertise and global resources with Embryyo’s decade-long experience in medical technology innovation.
Also Read: Vyome Therapeutics Completes Merger with ReShape Lifesciences; Nasdaq Debut Under Ticker HIND
The partnership aims to develop, productize, and commercialize smart medical devices designed to transform disease management and treatment standards worldwide.
“Vyome’s vision is to partner with top talent working on major healthcare challenges across the U.S.-India corridor in pharmaceuticals, AI, and medical devices. AI-enabled medical devices represent a significant opportunity, and Embryyo, founded by IIT alumni, is an ideal partner for this mission,” said Krishna Gupta, Chairman of Vyome Holdings.
Embryyo to Leverage Vyome’s Global Reach
Nishant Kumar, Co-Founder and CEO of Embryyo Technologies, stated, “We are excited about this partnership with Vyome as we share a common vision. Embryyo is currently building a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery. With Vyome’s access to global capital markets and the U.S. healthcare ecosystem, we will accelerate innovation and enhance global healthcare outcomes.”
Also Read: Quadria Group Launches $300M HealthQuad Fund III to Back Disruptive Healthcare Startups
Innovation Forum on AI-Enabled Medical Devices
As part of the MoU, Vyome and Embryyo will organize a global innovation forum focused on AI-enabled medical devices for companies along the U.S.-India healthcare corridor. The agreement is currently non-binding and may be subject to further conditions.
